This refresh
Data-driven refresh September 29, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,241 tickers); 1,706 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. DLO — DLocal Limited · score 89.1
Software - Infrastructure · price $13.69 · 1Y $18.80 · 5Y $27.53 · 10Y $40.83
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 20.1x B+ · PEG 0.59 A-
Why now. DLocal’s cross‑border pay‑in platform for global merchants is exploding, delivering 46.6% revenue growth YoY while keeping an 18% profit margin and a stellar ROE of 34.6%. Our Bull Rankings model rates the company 89.1/100, with Growth as the strongest pillar, confirming that the payment‑processing engine can keep compounding. The thesis rests on the relentless expansion of e‑commerce, streaming and ride‑hailing merchants that need DLocal’s unified payment suite, which should sustain double‑digit top‑line compounding for years to come.
Moat. DLocal’s “pay‑in for platforms” locks merchants into a single integration for hundreds of local cards, bank transfers and alternative payment methods, creating high switching costs and network effects. The 34.6% ROE reflects pricing power derived from being the preferred gateway for cross‑border transactions in emerging markets, a position hard for new entrants to replicate quickly.
Risk. The Bull Rankings model flags diluting shareholders and the reverse‑DCF shows the market pricing a -9% FCF growth in year 1, far below the 46.6% revenue surge just reported, suggesting the stock may already be assuming a sharp slowdown. A P/E of 20.3 is elevated for a growth name, and any further dilution or a sustained drop in growth would validate the bearish view that the current price is overly optimistic.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.53 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $40.83 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 88.7
Software - Application · price $233.17 · 1Y $278.15 · 5Y $407.25 · 10Y $604.12
FCF $10.6b A- · Rev +12.0% B+ · D/E 0.58 C+ · P/E 13.0x A- · PEG 0.57 A-
Why now. Adobe’s Digital Media subscription platform is the engine of relentless cash generation, delivering 12% revenue growth YoY while preserving a 28% profit margin and generating $10.6B of free cash flow. The Bull Rankings model rates the business at a Quality‑growth score of 88.7, with Quality as the strongest pillar, underscoring the durability of these margins and cash returns. The thesis hinges on the subscription moat continuing to compound cash at a rate that outpaces the modest –2% growth implied by the reverse‑DCF, making the current price a bargain on a high‑quality growth engine.
Moat. Adobe’s Digital Media suite locks in photographers, video editors, designers and enterprises on a subscription basis, creating high switching costs and predictable recurring revenue. The 61.9% ROE reflects pricing power derived from category leadership in creative software, while the integrated Digital Experience platform deepens customer stickiness across marketing and commerce workflows, a combination competitors cannot replicate quickly.
Risk. The market is pricing in a slowdown: the reverse‑DCF assumes free‑cash‑flow growth of –2% in year 1, far below the 12% trailing revenue growth, and a high beta of 1.42 amplifies downside in a volatile tech environment. If subscription renewal rates falter or competitors erode market share, the implied growth gap will widen, and the stock could retreat toward its 52‑week low of $190.12, confirming the bear case.
Horizon. 1-3 yr $278.15 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $407.25 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $604.12 if current growth sustains into durable earnings power.
3. NBIX — Neurocrine Biosciences, Inc. · score 87.6
Drug Manufacturers - Specialty & Generic · price $138.35 · 1Y $208.40 · 5Y $305.11 · 10Y $452.62
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 20.2x B+ · PEG 0.28 A
Why now. The bull case hinges on NBIX’s dominant position with INGREZZA in the high‑growth tardive‑dyskinesia market, where its FDA‑approved therapy fuels a 34.4% revenue growth run‑rate and a 20.9% profit margin. Coupled with a rock‑bottom PEG of 0.28, the company’s growth pillar (96) outshines the market, meaning earnings can keep compounding as the movement‑disorder franchise expands. The thesis rests on sustaining this product‑driven momentum.
Moat. NBIX’s moat derives from its patented oral formulation INGREZZA, the only FDA‑approved treatment for tardive dyskinesia, creating high switching costs for neurologists and patients. The drug’s specialty‑market pricing, combined with a low debt‑to‑equity of 0.12 and a near‑20% ROE, reflects pricing power that competitors cannot quickly replicate without costly clinical trials.
Risk. The bear case centers on the steep deceleration baked into the price: the reverse DCF assumes free‑cash‑flow growth of only 6% in year 1, far below the trailing 34.4% revenue growth. If the INGREZZA franchise stalls or new launches lag, the already modest 6% growth assumption could slip, crushing the valuation. A sustained slowdown would trigger a sell‑off, confirming the risk.
Horizon. 1-3 yr $208.40 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $305.11 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $452.62 if current growth sustains into durable earnings power.
4. HRMY — Harmony Biosciences Holdings, Inc. · score 86.9
Biotechnology · price $39.29 · 1Y $47.36 · 5Y $69.35 · 10Y $102.87
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.7x A- · PEG 0.46 A
Why now. HRMY’s dominant position with WAKIX, the only FDA‑approved narcolepsy therapy with a novel histamine‑based mechanism, fuels a revenue runway that is already expanding at 24.3% YoY. Coupled with an 18.9% profit margin and a solid 18.1% ROE, the Bull Rankings model awards a Quality‑Growth score of 86.9, where Growth is the strongest pillar, confirming that compounding earnings will persist as the narcolepsy market deepens. The thesis hinges on scaling WAKIX sales while the Phase‑3 PWS trial de‑risches, delivering the next wave of growth.
Moat. WAKIX’s patented mechanism of action creates a high barrier to entry; neurologists and sleep‑disorder specialists have built prescribing habits around its once‑daily oral dosing, and insurance formularies favor it over off‑label stimulants. This IP‑protected, specialty‑pharmacy distribution network translates into pricing power that underpins the current 18.1% ROE.
Risk. The price assumes a free‑cash‑flow growth trajectory starting at –17% and only easing to 3% by year 10, a clear sign that the market is pricing in a slowdown versus the 24.3% revenue growth just delivered; any delay in Phase‑3 PWS read‑out or failure to win additional indications would cement that pessimism and push the stock back toward its 52‑week low. A bear signal would be a missed PWS milestone, triggering a slide toward the lower end of the analyst target range.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.35 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $102.87 if current growth sustains into durable earnings power.
5. FICO — Fair Isaac Corporation · score 85.8
Software - Application · price $617.87 · 1Y $1,435 · 5Y $2,101 · 10Y $3,116
FCF $996m C+ · Rev +24.1% A- · D/E n/a · P/E 17.9x A- · PEG 0.69 A-
Why now. Software - Application · market cap $18.2b. Down 58% from 52-week high of $1998.01 — deep drawdown territory. Revenue growing +24%, comfortably above the S&P median. PEG 0.69 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $1,435 (implying +71% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 122% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Software economics — recurring revenue, embedded customer workflows, and high gross margin all compound the moat once a base account is won. Switching costs are the lever.
Risk. Down 58% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. ROE -20% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $1,435 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $2,101 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $3,116 if current growth sustains into durable earnings power.
6. INTU — Intuit Inc. · score 85.5
Software - Application · price $268.03 · 1Y $405.60 · 5Y $593.84 · 10Y $880.92
FCF $8.7b B+ · Rev +13.9% B+ · D/E 0.44 B · P/E 16.3x A- · PEG 0.88 B+
Why now. Our Bull Rankings model gives INTU a Quality‑growth score of 85.5, with Quality as the strongest pillar, underscoring the durable earnings power of its QuickBooks and Mailchimp platforms. The business is delivering 13.9% revenue growth YoY, 21.3% profit margin and generates $8.7 B of free cash flow – all at a modest PE of 16.4 and a PEG of 0.88, indicating cheapness relative to peers. Because the reverse‑DCF implies a starting FCF growth of –11% (well below the 13.9% revenue growth we just reported), the market is pricing in slower growth, leaving ample upside if the company sustains its current pace.
Moat. INTU’s moat lives in the sticky SMB ecosystem: QuickBooks ties small‑and‑mid‑market firms to integrated accounting, payroll, payments and financing, while Mailchimp adds cross‑sellable marketing tools. This deep integration creates high switching costs and a data advantage that fuels pricing power, reflected in a 24% ROE that stems from the company’s ability to monetize its entrenched customer base.
Risk. The bear case hinges on the market’s expectation of a slowdown – the reverse‑DCF assumes a –11% FCF growth rate, and any deceleration below the current 13.9% revenue growth would validate that pessimism. A modest debt‑to‑equity of 0.44 and a beta of 0.98 temper risk, but if growth stalls or margins compress, the stock could retreat toward its 52‑week low of $252.84, confirming the downside thesis.
Horizon. 1-3 yr $405.60 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $593.84 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $880.92 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 85.1
Semiconductors · price $227.21 · 1Y $327.70 · 5Y $479.79 · 10Y $711.73
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 28.7x B · PEG 0.47 A
Why now. NVIDIA’s Compute & Networking segment is the engine powering the AI data‑center boom, and that engine is revving at 83.4% revenue growth YoY while delivering a 63.7% profit margin and generating $127.0 billion of free cash flow. Those numbers prove the business can compound cash at break‑neck speed, and the 2026 analyst consensus of $327.70 (a 43% upside) underscores the market’s belief that AI demand will stay relentless. The thesis rests on the fact that AI‑driven compute spend will keep compounding for years to come.
Moat. NVIDIA’s moat lives in its AI‑optimized GPUs and networking stack that dominate the data‑center market, creating massive switching costs for cloud providers and enterprise customers. The staggering 84.2% ROE reflects pricing power that stems from being the de‑facto platform for generative AI workloads, a position rivals can’t replicate without years of R&D and ecosystem lock‑in.
Risk. The stock trades at a lofty PE of 29 with a beta of 2.22, meaning any slowdown in AI spend or a miss on the implied 47% year‑1 free‑cash‑flow growth (already below the 83% revenue surge) would yank the valuation hard. A sustained deceleration in revenue growth or a market‑wide risk‑off would validate the bear case, snapping the upside narrative.
Horizon. 1-3 yr $327.70 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $479.79 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $711.73 if current growth sustains into durable earnings power.
8. APP — AppLovin Corporation · score 83.8
Advertising Agencies · price $305.66 · 1Y $497.05 · 5Y $727.72 · 10Y $1,080
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 23.5x C+ · PEG 0.67 A-
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding platform, which is rapidly locking in premium inventory from top mobile publishers and compounding revenue at a breakneck pace. The business is delivering 60.6% revenue growth YoY while preserving a 64.6% profit margin, and our Bull Rankings model rates its Growth pillar at a stellar 96, lifting the overall Quality‑Growth score to 83.8. The market already prices in a slower 28% FCF growth trajectory versus the 60.6% revenue surge, meaning the upside is baked in – the thesis rests on the ability of MAX to keep accelerating cash conversion and push that implied growth higher.
Moat. MAX creates a sticky ecosystem: developers must integrate the real‑time auction to unlock the highest CPMs, and Adjust’s measurement suite locks them into a data‑rich feedback loop that competitors can’t replicate quickly. This high switching cost, combined with the network effect of more publishers feeding richer data into the AI engine, gives AppLovin a durable edge in the mobile ad stack.
Risk. The stock trades at a lofty PE of 23.5 despite a beta of 2.49, exposing it to market volatility and a valuation premium that could snap if growth decelerates or the AI bidding advantage erodes. A debt‑to‑equity ratio of 1.11 adds leverage risk if ad spend contracts, and any slowdown in the 60.6% revenue growth rate would validate the bearish view that the price is over‑optimistic. A breach of the 52‑week high at $738 would be the trigger that confirms the downside.
Horizon. 1-3 yr $497.05 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $727.72 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,080 if current growth sustains into durable earnings power.
9. CARG — CarGurus, Inc. · score 82.9
Internet Content & Information · price $31.16 · 1Y $42.00 · 5Y $61.49 · 10Y $91.22
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 16.1x B+ · PEG 0.67 A-
Why now. The Bull Rankings model gives CARG an 82.9/100 quality‑growth score, anchored by its strongest pillar – Quality – which reflects the company’s 66.6% ROE and robust 18.2% profit margin. The Digital Deal suite is unlocking higher‑margin transactions as the online car‑shopping audience expands, driving a 13.9% revenue growth rate that still outpaces the reverse‑DCF implied free‑cash‑flow growth of –6% in year 1. The thesis rests on this compounding margin‑rich growth continuing to outstrip the modest cash‑flow assumptions baked into today’s price.
Moat. CARG’s moat stems from its integrated marketplace that locks dealers into subscription fees while giving shoppers a seamless end‑to‑end experience via Digital Deal and Dealership Mode, creating a high‑switching‑cost network. The extraordinary 66.6% ROE is generated by pricing power that comes from being the go‑to platform for both large dealer groups and brand advertisers, a position competitors can’t replicate without building a comparable inventory of listings and data‑driven pricing tools.
Risk. The bear case focuses on the looming slowdown in cash‑flow growth: the reverse‑DCF model shows a starting –6% FCF growth, far below the trailing 13.9% revenue increase, indicating that earnings may not keep pace with sales if margin pressure rises. A P/E of 15.9, while modest, still reflects market expectations of continued growth; any miss on the Digital Deal rollout or a rise in debt‑to‑equity above 0.7 could push the valuation lower. A sustained dip below the 52‑week low of $26.39 would confirm the downside risk.
Horizon. 1-3 yr $42.00 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $61.49 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $91.22 if current growth sustains into durable earnings power.
10. KTB — Kontoor Brands, Inc. · score 82.9
Apparel Manufacturing · price $64.29 · 1Y $97.50 · 5Y $142.75 · 10Y $211.76
FCF $422m C · Rev +34.3% A · D/E 2.06 C · P/E 13.1x A- · PEG 0.54 A-
Why now. Apparel Manufacturing · market cap $3.5b. Down 27% from 52-week high of $88.96 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.54 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $97.50 (implying +50% upside).
Moat. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 158% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $97.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $142.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $211.76 if current growth sustains into durable earnings power.
11. DOCS — Doximity, Inc. · score 82.6
Health Information Services · price $26.52 · 1Y $29.94 · 5Y $43.84 · 10Y $65.04
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 31.6x B · PEG 0.59 A-
Why now. The bull case for Doximity rests on its highly profitable, cash-generative platform for medical professionals, which continues to compound value. With a free cash flow of $306m against a modest $4.7b market cap, the company boasts a robust FCF yield, further supported by a strong 25.5% profit margin. Our Bull Rankings model assigns DOCS an impressive Quality-growth score of 82.6/100, with Quality as its strongest pillar at 88, signaling a fundamentally sound business model. The crux is Doximity's ability to monetize its engaged professional user base through sponsored content from pharmaceutical manufacturers and health systems, and its expanding suite of workflow tools like the HIPAA-compliant AI assistant, Ask.
Moat. Doximity's enduring competitive advantage stems from its deeply embedded digital platform within the daily workflows of U.S. medical professionals, fostering a powerful network effect. The personalized newsfeed, offering clinical content and professional updates, along with HIPAA-compliant workflow tools like Ask and Scribe, creates significant switching costs for its members. This proprietary ecosystem makes Doximity an indispensable channel for pharmaceutical manufacturers and health systems to reach medical professionals, a position difficult for competitors to replicate quickly due to the regulatory hurdles and trust required in healthcare.
Risk. The primary risk for Doximity is a deceleration in its core revenue growth, which currently stands at 11.2% TTM YoY, potentially failing to justify its current valuation given the market's expectations for a "growth" category stock. Our Bull Rankings model's weakest pillar for DOCS is Value (75), indicating that while not expensive, the market isn't pricing in a significant re-rating despite the current price implying free-cash-flow growth of about 9% a year in year 1, roughly in line with trailing revenue growth. Furthermore, the stock's beta of 1.25 suggests higher volatility, making it susceptible to broader market downturns. A concrete signal confirming the bear case would be a sustained decline in engagement metrics on the Doximity platform, leading to reduced advertising spend from pharmaceutical manufacturers and health systems.
Horizon. 1-3 yr $29.94 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.84 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $65.04 if current growth sustains into durable earnings power.
12. EXLS — ExlService Holdings, Inc. · score 82.1
Information Technology Services · price $34.58 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 21.9x B+ · PEG 0.90 B+
Why now. The bull case hinges on EXLS’s dominant AI‑driven claims management platform, which is scaling at a 13.4% revenue growth YoY while generating $297 m of free cash flow and delivering a stellar ROE of 32.3%. Our Bull Rankings model awards a Quality‑Growth score of 82.1, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the continuation of high‑margin AI services that keep cash flowing into buybacks and fuel further expansion.
Moat. EXLS locks in insurers and health providers with integrated AI analytics for claims processing and underwriting, creating high switching costs because clients rely on proprietary data models and real‑time actuarial insights. This stickiness translates into the 32.3% ROE, reflecting pricing power derived from category leadership in AI‑enabled digital operations across Insurance, Healthcare, and Banking.
Risk. The bear case centers on the valuation gap: a forward P/E of 21.9 already embeds a modest growth premium, yet the Bull Rankings model’s reverse DCF assumes free‑cash‑flow growth of only 4% in year 1, well below the 13.4% revenue pace, indicating the market may be pricing in a slowdown. A miss on AI adoption or a rise in debt‑to‑equity above 0.57 would push the P/E higher and erode margins, confirming the downside.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
13. CPAY — Corpay, Inc. · score 81.1
Software - Infrastructure · price $392.70 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.0x B+ · PEG 0.76 A-
Why now. The bull case hinges on Corpay’s dominant corporate‑payments platform, especially its cross‑border and virtual‑card solutions that lock in large enterprise spend. The business is delivering 20.4% revenue growth YoY, 22.7% profit margin, and a massive $1.6 B free‑cash‑flow run‑rate, all while the Bull Rankings model flags a strong Growth pillar (92) and a buy‑back signal. The thesis rests on the ability to keep compounding that spend‑management moat as corporate expense budgets expand.
Moat. Corpay’s moat lives in its integrated spend‑management suite—virtual cards, AP modernization, and cross‑border payments—that embeds deep workflow and compliance hooks for Fortune‑500 clients, creating high switching costs. The 32.2% ROE reflects pricing power derived from being the preferred provider for large‑scale corporate expense programs, a position competitors can’t replicate quickly without costly integrations.
Risk. The bear case centers on the valuation gap: a forward P/E of 24.1 is lofty for a name whose reverse‑DCF assumes only 3% free‑cash‑flow growth, far below the 20.4% revenue surge just reported. Coupled with a debt‑to‑equity of 2.75, any slowdown in corporate spend or a rise in financing costs would compress margins and force the stock toward its 52‑week low of $252.84. A breach of the 3% growth assumption would validate the downside.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
14. LRN — Stride, Inc. · score 81
Education & Training Services · price $75.59 · 1Y $88.16 · 5Y $129.07 · 10Y $191.47
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 10.6x A · PEG 0.43 A
Why now. Stride’s integrated online platform for software engineering and healthcare curricula creates a sticky, state‑customized learning ecosystem that drives high cash conversion. The business generates $433 m of free cash flow on a $3.2 b market cap, delivering a 13.4% profit margin and a stellar ROE of 20.7%. Coupled with a PEG of 0.43, the stock trades at a P/E of 10.7, making it the cheapest peer in the sector; the thesis rests on the continued capture of state‑funded enrollment and disciplined buybacks that amplify returns.
Moat. The platform’s single‑sign‑on architecture ties curriculum, learning management, student information, and analytics into one seamless system, creating high switching costs for K‑12 districts and post‑secondary partners. This lock‑in, combined with the ability to deliver state‑customized courses, fuels pricing power that underpins the 20.7% ROE, a margin advantage competitors can’t quickly replicate.
Risk. Revenue is only growing at a modest 4.7% YoY, and the Bull Rankings model’s reverse‑DCF assumes free‑cash‑flow growth of –13% in year 1, indicating the market doubts sustainable expansion. The stock’s 52‑week high of $155.06 versus today’s $76.66 reflects a steep de‑rating, and any slowdown in state funding or a shift to alternative ed‑tech platforms would validate the bearish view. A further miss on enrollment would trigger a sell‑off, confirming the risk.
Horizon. 1-3 yr $88.16 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $129.07 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $191.47 if current growth sustains into durable earnings power.
15. DECK — Deckers Outdoor Corporation · score 80.7
Footwear & Accessories · price $77.68 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.0x A- · PEG 0.96 B+
Why now. Deckers' UGG and HOKA footwear lines are riding a durable premium‑price premium in the casual‑lifestyle and high‑performance segments, delivering 44.1% ROE, 18.4% profit margin and 7.9% revenue growth YoY, while the stock trades at a PE of 11.1—far below its 52‑week high of $122.29. Our Bull Rankings model flags a Quality score of 96, the strongest pillar, confirming that the business’s earnings power is robust. The thesis rests on the continued compounding of high‑margin UGG and HOKA sales, which should keep returns soaring and justify the upside to the analyst consensus target.
Moat. Deckers locks in pricing power through category leadership in premium casual and performance footwear—UGG dominates the upscale sheepskin market and HOKA leads the high‑cushion running segment—creating a pricing premium that fuels its 44.1% ROE. Its direct‑to‑consumer and selective retail distribution network, combined with brand‑specific product innovation, raises switching costs for consumers who value the distinct comfort and style of these lines.
Risk. The stock’s valuation still reflects optimism: the reverse‑DCF shows implied free‑cash‑flow growth starting at –5% and only reaching low‑single‑digit growth by year 10, well below the trailing 7.9% revenue growth, indicating that any slowdown in UGG or HOKA demand could crush the upside. A beta of 1.15 amplifies market volatility, and the modest debt‑to‑equity of 0.21 offers little cushion if a macro‑downturn forces margin compression. A sustained miss on quarterly earnings would trigger the bear signal and invalidate the growth assumptions.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 80.5
Information Technology Services · price $107.14 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.5x A- · PEG 0.58 A-
Why now. EPAM is a deeply undervalued growth play in the critical digital transformation space, with its core engineering, cloud, and AI services driving substantial free cash flow. A compelling PEG ratio of 0.58 and $483m in free cash flow against a $5.5b market cap highlight a significant disconnect between valuation and operational strength. Our model's strongest pillar, Value (86/100), confirms this cheapness, as the current price implies FCF growth of only ~4% annually, well below its 10.8% trailing revenue growth, suggesting pessimism is already priced in. The market is underestimating EPAM's compounding power in digital engineering as it actively buys back stock.
Moat. EPAM's durable edge stems from its deep expertise in mission-critical digital platform engineering and software development services, encompassing everything from requirements analysis to cross-platform migration and integration. The complexity and embedded nature of its cloud, data, analytics, and artificial intelligence solutions create significant switching costs for clients, making it difficult and costly to replace EPAM once integrated into their core operations. This specialized capability in high-demand areas like cybersecurity ensures persistent client reliance and recurring revenue streams.
Risk. Skeptics would point to EPAM's high beta of 1.38 as a significant risk, indicating its susceptibility to broader economic downturns that could curtail client spending on discretionary digital platform engineering and cloud services. The stock's sharp decline from its 52-week high of $222.53 to the current $107.55 suggests the market has already priced in concerns about future growth or margin pressure. Our model's softest pillar, Quality (74/100), while not poor, flags this potential sensitivity, as a sustained contraction in client project pipelines or increased competition for its data, analytics, and AI services would confirm the bear case.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
17. PRDO — Perdoceo Education Corporation · score 80.1
Education & Training Services · price $30.11 · 1Y $34.51 · 5Y $50.53 · 10Y $74.96
FCF $221m C · Rev +11.7% B · D/E 0.11 A · P/E 10.9x A- · PEG 0.62 A-
Why now. The bull case hinges on AIUS’s fast‑growing health‑care and cybersecurity programs, which are fueling a 11.7% revenue growth while the business delivers a solid 20.6% profit margin and a free‑cash‑flow haul of $221 m. Our Bull Rankings model gives PRDO an 80.1/100 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its earnings engine. Because the reverse‑DCF implies a -15% FCF growth rate in year 1—well below the 11.7% top‑line growth the market is already pricing in—the stock is effectively discounted for future slowdown, making the current price a launchpad for upside.
Moat. PRDO’s moat lives in its integrated online‑learning platform that serves career‑oriented students across CTU, AIUS and USAHS, creating high switching costs for learners who have already invested in credits, certifications and employer partnerships. The 17.1% ROE reflects pricing power in niche, high‑demand programs like nursing and cybersecurity, where few competitors can match PRDO’s blended delivery model and federal aid expertise.
Risk. The bear case centers on the looming deceleration implied by the reverse‑DCF: a -15% FCF growth rate in year 1 signals that cash generation could stall despite the 11.7% revenue rise, and a P/E of 10.9, while low, may already embed pessimism about future margins. If the revenue growth dips below 10% or profit margins compress, the stock’s 0.72 beta and modest debt‑to‑equity of 0.11 won’t shield it, and a breach of the 52‑week low at $26.66 would confirm the downside.
Horizon. 1-3 yr $34.51 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $50.53 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $74.96 if current growth sustains into durable earnings power.
18. CVSA — Covista Inc. · score 79.5
Education & Training Services · price $119.45 · 1Y $159.50 · 5Y $233.52 · 10Y $346.42
FCF $393m C · Rev +9.3% B · D/E 0.63 B+ · P/E 15.9x B+ · PEG 0.89 B+
Why now. The bull case hinges on Covista’s dominant position in online health‑profession education, especially the Chamberlain University segment, which feeds a steady pipeline of nursing and allied‑health students. The business is delivering 9.3% revenue growth YoY, a solid 12.9% profit margin, and a free‑cash‑flow generation of $393 m, all while trading at a modest P/E of 15.9—a clear value cushion. With our model’s strongest pillar, Quality, scoring 80, the thesis rests on the persistence of this compounding growth in a market that still needs more qualified health workers.
Moat. Covista’s moat stems from its accredited, fully online degree pathways in nursing, medical, and veterinary fields, which create high switching costs for students who have already invested years of tuition and credit hours. The Chamberlain and Walden brands command pricing power in a regulated education market, driving a ROE of 17.4% that reflects efficient capital use and a defensible cost structure that rivals can’t replicate quickly.
Risk. The bear case focuses on the reverse‑DCF implied cash‑flow trajectory: the market assumes a -12% growth rate in year 1, well below the trailing 9.3% revenue growth, signaling that investors are already pricing in a slowdown. Coupled with a debt‑to‑equity of 0.63, any further leverage or a slowdown in enrollment could compress margins and erode the current P/E advantage. A breach of the -12% growth assumption would confirm the downside.
Horizon. 1-3 yr $159.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $233.52 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $346.42 if current growth sustains into durable earnings power.
19. RMD — ResMed Inc. · score 79.1
Medical Instruments & Supplies · price $222.83 · 1Y $250.22 · 5Y $366.35 · 10Y $543.46
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.3x B+ · PEG 1.29 B
Why now. Medical Instruments & Supplies · market cap $32.0b. Down 22% from 52-week high of $284.87 — deep drawdown territory. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $250.22 (implying +13% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $250.22 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $366.35 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $543.46 if current growth sustains into durable earnings power.
20. DXCM — DexCom, Inc. · score 78.6
Medical Devices · price $86.64 · 1Y $94.48 · 5Y $138.33 · 10Y $205.20
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.2x C+ · PEG 1.33 B
Why now. The Bull Rankings model gives DexCom a 78.6/100 quality‑growth score, anchored by a strongest pillar of Quality and a softest pillar of Value, meaning the stock trades on the cheap side of its peers while the business itself is top‑tier. The G7 and G7 15‑Day CGM platforms are expanding rapidly, delivering 15.5% revenue growth YoY and a 20.1% profit margin that fuels a free‑cash‑flow stream of $1.4 B. With a ROE of 38.1% and a reverse‑DCF implying 23% FCF growth in year 1 (well above the 15.5% revenue pace), the upside rests on the continued compounding of high‑margin CGM adoption.
Moat. DexCom’s moat comes from its integrated CGM ecosystem – the G7 hardware, Dexcom Share remote monitoring, and the Follow app – which lock in endocrinologists and patients through data continuity and FDA‑cleared accuracy that rivals cannot replicate quickly. The 38.1% ROE reflects pricing power derived from category leadership in continuous glucose monitoring, allowing the firm to reinvest cash into product upgrades while maintaining strong cash returns.
Risk. The bear case hinges on the elevated PE of 34.2 and a beta of 1.42, indicating market expectations are already high and the stock is sensitive to any slowdown; if revenue growth falls below the 15.5% trend or margins compress, the 23% FCF growth assumption collapses, triggering a sell‑off. A confirmation of this risk would be a miss on the next quarterly revenue or margin guidance, pushing the price back toward the 52‑week low of $54.11.
Horizon. 1-3 yr $94.48 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $138.33 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $205.20 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 78.3
Internet Retail · price $1724.90 · 1Y $2,272 · 5Y $3,327 · 10Y $4,935
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 48.0x D · PEG 0.96 B+
Why now. MercadoLibre’s Mercado Pago platform is the engine of its explosive 46% revenue growth and fuels a $12.4B free‑cash‑flow runway, while a ROE of 23.8% shows capital is being deployed profitably. Our Bull Rankings model awards a 78.3 quality‑growth score, with Growth as the strongest pillar, underscoring that the business can keep compounding. The reverse‑DCF assumes a modest –9% FCF growth in year 1, well below the 46% top‑line pace just delivered, meaning the market is pricing in pessimism – the upside is baked into the stock.
Moat. The integrated Mercado Pago and Mercado Envios ecosystem creates a two‑sided network that locks sellers and buyers into a single payments‑logistics loop, raising switching costs and enabling MercadoLibre to capture fees across the transaction chain. This network, combined with a ROE of 23.8% from pricing power in Latin America’s leading e‑commerce marketplace, gives the firm a durable edge competitors can’t replicate quickly.
Risk. The stock trades at a lofty PE of 46.5 and a debt‑to‑equity of 1.69, while beta of 1.31 signals heightened volatility; the reverse‑DCF already assumes growth will tumble to single‑digit levels. If revenue growth stalls below the historic 46% pace, margins compress and the high multiple will implode, likely pulling the price back toward its 52‑week low of $1,495.
Horizon. 1-3 yr $2,272 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $3,327 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $4,935 if current growth sustains into durable earnings power.
22. YUMC — Yum China Holdings, Inc. · score 78.3
Restaurants · price $40.80 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 14.9x B+ · PEG 0.90 B+
Why now. Yum China’s KFC franchise is still the fastest‑growing quick‑service brand in the world, and its relentless same‑store expansion in second‑tier Chinese cities fuels a compounding revenue engine. The business delivered 8.8% revenue growth YoY while generating $940m of free cash flow and trades at a modest PE of 15.1, leaving ample headroom for a multi‑year earnings surge. The entire thesis rests on the ability of KFC’s localized menu and delivery network to keep compounding this growth.
Moat. Yum China’s moat comes from its dense KFC and Pizza Hut footprint that couples a proprietary supply chain with a best‑in‑class delivery platform, locking in urban diners and office workers who value speed and consistency. This operating scale underpins an ROE of 18.2%, driven by pricing power in a market where few rivals can match the brand‑level logistics and localized menu innovation.
Risk. The bear case hinges on the market’s implicit assumption of slower growth: the Bull Rankings reverse‑DCF model values the stock on a 4% cash‑flow growth rate that trails the 8.8% revenue growth just reported. If top‑line momentum stalls to the implied 4% level, the current PE of 15.1 will look stretched and the share price could tumble toward the 52‑week low of $40.15. A sustained slowdown in KFC same‑store sales would confirm this risk.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
23. BSX — Boston Scientific Corporation · score 77.8
Medical Devices · price $43.88 · 1Y $61.00 · 5Y $89.31 · 10Y $132.49
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 17.8x A- · PEG 0.62 A-
Why now. Boston Scientific’s dominant position in the Cardiovascular and MedSurg segments lets it capture the booming demand for minimally invasive endoscopic tools, driving a 13.5% revenue growth and a healthy 17.5% profit margin. Coupled with a robust $3.6 B free‑cash‑flow and a PEG of 0.62, the Bull Rankings model awards a 77.8 quality‑growth score, with Growth as its strongest pillar, indicating the business can keep compounding on its clinical leadership. The thesis hinges on sustaining this growth trajectory as hospitals expand minimally invasive procedures.
Moat. BSX’s MedSurg segment supplies single‑use duodenoscopes and SpyGlass systems that hospitals adopt for infection‑critical ERCP procedures, creating high switching costs and a lock‑in to its proprietary delivery platforms. Its 14.7% ROE stems from pricing power in these niche, regulated device categories where clinical data and FDA clearance act as barriers to entry, limiting fast‑copycat competition.
Risk. The bear case centers on the price assuming a slowdown: the reverse‑DCF shows implied free‑cash‑flow growth starting at –2% and only reaching 3% by year 10, well below the trailing 13.5% revenue growth, suggesting pessimism is baked in. If the next wave of device innovations stalls or reimbursement tightens, the modest 0.5 debt‑to‑equity ratio could rise, and the stock’s low beta (0.57) offers little upside momentum, confirming the downside if growth decelerates.
Horizon. 1-3 yr $61.00 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $89.31 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $132.49 if current growth sustains into durable earnings power.
24. ACN — Accenture plc · score 77.5
Information Technology Services · price $177.12 · 1Y $193.03 · 5Y $282.61 · 10Y $419.24
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 14.1x A- · PEG 1.28 B
Why now. Accenture’s unmatched depth in cloud‑enabled digital transformation – its intelligent platform and AI‑driven services – fuels a compounding engine that will keep revenue expanding at 6.7% YoY while free cash flow remains robust at $12.6 B. The Bull Rankings model rates its Quality at 89, confirming a high‑margin, high‑ROE engine (24.4%) that can sustain dividend hikes, and the market already prices in a modest growth outlook, leaving upside for the next earnings beat. The thesis rests on the continued capture of large‑enterprise contracts in the cloud and AI space.
Moat. Accenture’s end‑to‑end delivery model locks in multi‑year engagements across strategy, systems integration and managed services, creating high switching costs for Fortune‑500 clients. Its 24.4% ROE reflects pricing power derived from category leadership in AI‑cloud implementations, where few rivals can match its global delivery network and deep industry expertise.
Risk. The reverse‑DCF shows the stock assumes a near‑term free‑cash‑flow contraction of –8% before easing to 3% by year 10, a pace well below the 6.7% revenue growth just delivered, implying the market is already pricing in a slowdown. Coupled with a beta of 1.09 and a modest debt‑to‑equity of 0.25, any miss on the growth trajectory or a shift to lower‑margin projects would validate the bearish view and trigger a price correction.
Horizon. 1-3 yr $193.03 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $282.61 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $419.24 if current growth sustains into durable earnings power.
25. AVGO — Broadcom Inc. · score 77.1
Semiconductors · price $355.10 · 1Y $531.85 · 5Y $778.68 · 10Y $1,155
FCF $39.4b A · Rev +48.7% A · D/E 0.60 C+ · P/E 45.2x C+ · PEG 0.35 A
Why now. Broadcom’s explosive 48.7% revenue growth in the trailing twelve months, powered by its Semiconductor Solutions segment’s custom silicon and Ethernet switching wins, fuels a compounding engine that our model flags as the strongest pillar – Growth – in its 77.1/100 quality‑growth score. Coupled with a 42.9% profit margin and a massive $39.4 B free‑cash‑flow haul, the business is set to reinvest and return capital at a pace that compounds earnings well beyond the next few years. The thesis rests on sustained demand for high‑performance networking and wireless connectivity, which should keep the growth trajectory alive.
Moat. AVGO’s moat lives in its deep integration with hyperscale data‑center customers via custom silicon, Ethernet NIC controllers, and fiber‑optic components that lock‑in multi‑year contracts and create switching costs that rivals can’t quickly replicate. Its 38.4% ROE reflects pricing power derived from category leadership in high‑margin server and storage solutions, where design expertise and IP‑heavy ASICs command premium pricing.
Risk. The bear case centers on the lofty 45.2 P/E, which signals that the market has already priced in a premium for growth that may be hard to sustain as the reverse‑DCF shows year‑1 FCF growth of 41% tapering to just 3% by year 10, below the 48.7% revenue surge just delivered. A slowdown in data‑center spend or a successful cost‑cutting push from rivals could compress margins and force management to slow or reverse dividend increases, confirming the downside.
Horizon. 1-3 yr $531.85 (analyst consensus (n=47)) — fundamentals + valuation re-rating. 5 yr $778.68 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,155 if current growth sustains into durable earnings power.
26. NFLX — Netflix, Inc. · score 76.7
Entertainment · price $70.30 · 1Y $92.93 · 5Y $136.05 · 10Y $201.83
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 22.1x B · PEG 1.22 B
Why now. Netflix’s global streaming platform is locked into a massive, ever‑growing subscriber base that now fuels a 28.2% profit margin and a 45.3% ROE, delivering $11.2 B of free cash flow while revenue still expands at 16% YoY. That combination of cash generation and high returns lets the company reinvest in premium originals and interactive games, compounding growth for years to come. The thesis rests on the ability to keep scaling that cash‑rich, high‑margin engine.
Moat. The moat lives in Netflix’s proprietary content library and its seamless delivery across TVs, set‑top boxes and mobiles, which creates a high switching cost for members who have built personal watch habits. Its 45.3% ROE reflects pricing power that only a category‑leading streaming service with a global footprint can sustain, and rivals must spend billions to match the breadth of its catalog and device integration.
Risk. The stock trades at a lofty 21.8 × forward earnings and a beta of 1.53, meaning any slowdown in subscriber growth or a dip in the high‑margin mix could quickly erode the premium valuation. Moreover, the Bull Rankings model’s reverse‑DCF assumes a 28% FCF growth rate in year 1—far above the 16% revenue growth actually delivered—so a miss on that growth premium would trigger a sharp correction. A sustained decline in margin or a rise in debt‑to‑equity above 0.55 would confirm the bear case.
Horizon. 1-3 yr $92.93 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $136.05 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $201.83 if current growth sustains into durable earnings power.
27. VRT — Vertiv Holdings Co · score 76.7
Electrical Equipment & Parts · price $248.34 · 1Y $338.22 · 5Y $495.19 · 10Y $734.58
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 56.1x D · PEG 0.85 B+
Why now. Electrical Equipment & Parts · market cap $94.0b. Down 36% from 52-week high of $379.94 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. PEG 0.85 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $338.22 (implying +39% upside).
Moat. Net margin 15% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 169% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trailing P/E 55.1x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.08 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $338.22 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $495.19 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $734.58 if current growth sustains into durable earnings power.
28. HALO — Halozyme Therapeutics, Inc. · score 76.6
Biotechnology · price $111.56 · 1Y $99.56 · 5Y $145.76 · 10Y $216.22
FCF $806m C+ · Rev +41.2% A · D/E n/a · P/E 32.7x C+ · PEG 1.56 C+
Why now. Halozyme’s rHuPH20 platform unlocks sub‑cutaneous delivery for high‑growth biologics, letting partners launch larger‑dose antibodies faster and cheaper. The business just posted 41.2% revenue growth YoY, a 24.9% profit margin, and generated $806 m of free cash flow, all while trading at a premium (our model flags Value at 48). The bull case hinges on the Growth pillar – our model scores Growth at 97 – because the enzyme‑enhanced delivery market is still expanding and Halozyme’s partner pipeline should keep compounding revenue for years to come.
Moat. The patented recombinant human hyaluronidase (rHuPH20) is the core IP that lets Halozyme embed its enzyme into partner biologics, creating a high switching cost for customers who have built formulation processes around it. This proprietary enzyme, delivered via the Hylenex formulation, gives Halozyme a unique foothold in the sub‑cutaneous biologics space that rivals cannot replicate quickly.
Risk. The stock trades at a lofty PE of 32.7 despite a 41.2% revenue surge, implying the market already priced in near‑term hype; any slowdown toward the model‑implied 3% free‑cash‑flow growth would trigger a sharp re‑rating. A bear‑case materializes if partner pipelines stall or competitors launch alternative enzyme platforms, compressing margins and forcing the valuation down toward sector averages.
Horizon. 1-3 yr $99.56 (analyst consensus (n=9)) — fundamentals + valuation re-rating. 5 yr $145.76 at ~5% CAGR — compounding case rests on the competitive position widening. 10 yr $216.22 if current growth sustains into durable earnings power.
29. WMG — Warner Music Group Corp. · score 76.3
Entertainment · price $27.62 · 1Y $37.75 · 5Y $55.27 · 10Y $81.99
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 22.1x B · PEG 0.49 A
Why now. Our Bull Rankings model gives WMG a 76.3 quality‑growth score, with Growth as the strongest pillar, because its Recorded Music segment is still expanding at a 12.9% revenue‑growth rate while generating $836 m of free cash flow and delivering a staggering 78.7% ROE. That combination of high‑margin cash generation and accelerating top‑line growth fuels a compounding engine that can keep the business expanding for years to come. The thesis rests on the ability of its two‑million‑song catalog to keep monetizing streaming and licensing at ever‑higher rates.
Moat. Warner Music’s moat lives in its deep, owned catalog of roughly two million compositions and the exclusive rights it licenses to streaming platforms, advertisers, and film producers. This IP base creates a pricing advantage that translates into the extraordinary 78.7% ROE, as rivals must pay premium fees to access the same hits and cannot quickly replicate the breadth of WMG’s rights. The recurring licensing streams also lock in cash flow that is hard for new entrants to displace.
Risk. The bear case centers on the fact that the stock trades at a forward‑looking P/E of 21.7, well above the sector’s average, while the Bull Rankings model flags a softest pillar of Value at 70 – still on the cheap side but indicating the price is not a deep discount. Moreover, the reverse‑DCF shows the market is already pricing in a 13% FCF growth rate that tapers to 3% by year 10, a trajectory that may be optimistic if revenue growth slows from the current 12.9% pace. A sustained dip in streaming royalties or a rise in debt‑to‑equity above the current 4.53 would confirm the downside and break the bull thesis.
Horizon. 1-3 yr $37.75 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $55.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $81.99 if current growth sustains into durable earnings power.
30. CI — The Cigna Group · score 75.8
Healthcare Plans · price $275.26 · 1Y $341.83 · 5Y $500.48 · 10Y $742.43
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.4x A · PEG 0.74 A-
Why now. The bull case hinges on Evernorth’s expanding pharmacy‑benefit management franchise, which is driving double‑digit top‑line momentum. Cigna’s 11.3% FY revenue growth, bolstered by $9.1 B of free cash flow and a low‑beta profile (0.32), gives the business a cash‑rich runway to reinvest in specialty and whole‑person health services. Our Bull Rankings model scores CI at 75.8/100, with Growth as the strongest pillar, underscoring that the compounding engine in Evernorth will keep compounding for years to come. The thesis rests on the persistence of this growth premium.
Moat. Evernorth’s integrated pharmacy‑benefit platform creates high switching costs for large employers and health plans, tying them to Cigna’s formulary design, utilization review, and specialty distribution network. This lock‑in fuels a stable ROE of 16.8%, reflecting pricing power that rivals can’t quickly replicate without building a comparable network and data‑driven clinical programs.
Risk. The bear case centers on the modest profit margin of 2.3% and a debt‑to‑equity of 0.74, which could tighten if reimbursement rates fall or regulatory pressure squeezes pharmacy spreads. A slowdown in revenue growth below the trailing 11.3% would validate the reverse‑DCF’s implied negative FCF growth in year 1 and could push the stock back toward its 52‑week low of $239.51. A breach of the 52‑week low would signal the downside is materializing.
Horizon. 1-3 yr $341.83 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $500.48 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $742.43 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.